Table 1.
Demographic and baseline characteristics (All PsA ixekizumab-exposure safety population)
| Characteristics | All-IXE treatment periods(N = 1118) |
|---|---|
| Age, years, mean (SD) | 49.5 (11.9) |
| Sex, n (%) | |
| Male | 517 (46.2) |
| Female | 601 (53.8) |
| Race, n (%) | |
| White | 1056 (94.5) |
| Asian | 39 (3.5) |
| American Indian or Alaska Native | 9 (0.8) |
| Multiple | 8 (0.7) |
| Black or African American | 4 (0.4) |
| Native Hawaiian or other Pacific Islander | 1 (0.1) |
| Weight, kg, mean (SD) | 86.31 (20.4) |
| BMI, kg/m2, mean (SD) | 29.95 (6.9) |
| Previous PsA systemic therapya, n (%) | |
| No prior treatment | 218 (19.5) |
| Non-biologic only | 562 (50.3) |
| Biologic only | 71 (6.4) |
| Biologic and non-biologic | 267 (23.9) |
| Duration of PsA symptoms in years, mean (SD) | 9.71 (8.7) |
All-IXE treatment period defined as all patients who received ≥ 1 dose of IXE
aSystemic therapy includes biologic (such as anti-TNF inhibitors) and non-biologic (such as cDMARDs, NSAIDs, and corticosteroids) medications that were used prior to the study entry
bDMARDs biologic disease-modifying antirheumatic drugs, BMI body mass index, cDMARDs conventional disease-modifying antirheumatic drugs, IXE ixekizumab, N population size, n number in each group, NSAIDs non-steroidal anti-inflammatory drugs, PsA psoriatic arthritis, SD standard deviation